Similar Papers

Paper Title
Journal
Date
Author
Abstract 239: Assessment of immunotherapeutic efficacy of entinostat by using the 3d-explore ex vivo platform utilizing tumoroids of fresh patient tumor samples with intact tumor microenvironment
Krithika Nandakumar Kodumudi ... Olivia Macintosh
Cancer Research | VOL. 82
Krithika Nandakumar Kodumudi, et. al.Krithika Nandakumar Kodumudi ... Olivia Macintosh
15 Jun 2022
Abstract 246: Application of the 3d fresh patient tumoroid platform 3d-explore to assess the immunomodulatory and phagocytic activity of the receptor tyrosine kinase inhibitor, Sunitinib
Brittany Bunch ... Kelly Sussman
Cancer Research | VOL. 82
Brittany Bunch, et. al.Brittany Bunch ... Kelly Sussman
15 Jun 2022
Abstract 288: An ex-vivo 3D tumoroid model of fresh patient tissue (3D-EXplore) to assess transcriptional and compositional changes of the immune landscape in intact tumor microenvironment using single-cell proteogenomics
Jonathan P Waterman-Smith ... Olivia Macintosh
Cancer Research | VOL. 82
Jonathan P Waterman-Smith, et. al.Jonathan P Waterman-Smith ... Olivia Macintosh
15 Jun 2022
Abstract 1501: Employing 3D-ACT platform to assess the ability of stromal-targeting agents to improve penetration and efficacy of cell therapy
Zhisong Tong ... Mibel M Pabón
Cancer Research | VOL. 81
Zhisong Tong, et. al.Zhisong Tong ... Mibel M Pabón
01 Jul 2021
View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title
Journal
Date
Author
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
Daniel J Landsburg ... Cameron J Turtle
Journal for ImmunoTherapy of Cancer | VOL. 13
Daniel J Landsburg, et. al.Daniel J Landsburg ... Cameron J Turtle
09 Feb 2025
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma
Ramya Ramaswami ... Chia-Ching Jackie Wang
Journal for ImmunoTherapy of Cancer | VOL. 13
Ramya Ramaswami, et. al.Ramya Ramaswami ... Chia-Ching Jackie Wang
06 Feb 2025
Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes
Troels Holz Borch ... Inge Marie Svane
Journal for ImmunoTherapy of Cancer | VOL. 13
Troels Holz Borch, et. al.Troels Holz Borch ... Inge Marie Svane
06 Feb 2025
Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study
Michiel M Smeenk ... Willemijn S M E Theelen
Journal for ImmunoTherapy of Cancer | VOL. 13
Michiel M Smeenk, et. al.Michiel M Smeenk ... Willemijn S M E Theelen
06 Feb 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.